Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELU001 in Pediatric AML
NCT05622591Phase 1Withdrawn
- Sponsor
- Elucida Oncology, Inc.
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs), Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ELU001 in acute myeloid leukemia (AML), sponsored by Elucida Oncology, Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Planned start Jun 2024; status: withdrawn.
02
Drugs
ELU001
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05622591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622591.